Publication | Closed Access

Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial

ThrombosisStroke OnsetIschemic StrokeCardiovascular DiseaseMedicineCerebrovascular DiseaseRehabilitationNeurologyCerebral Blood FlowPublic HealthStrokeNeurological AssessmentIschemic SyndromeAcute Ischaemic StrokePhase 3